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ABSTRACT 
Background: Chronic kidney diseases (CKD) is characterized by glomerulosclerosis, tubular injury, and 
proteinuria. Neprin is the one of the most important protein involved in glomerular filtration but the mechanism 
of nephrin expression in chronic kidney failure is not well understood.  
Objective: We aims to elucidate the correlation between nephrin expression with tubular injury and serum 
creatinine level.  
Methods: We performed 5/6 subtotal nephrectomy (SN) in male strain Swiss mice to induce CKD. Sham operation 
was performed to control group (SO) (n=8). Mice were sacrificed in day 7 (SN7; n=8) and day 28 (SN28; n=8) 
after operation. We measure creatinine serum level to assess renal function. Tubular injury score was quantified 
using Periodic Acid Schiff (PAS) staining. Reverse transcriptase PCR (RT-PCR) was carried out to examine 
Nephrin mRNA expression. 
Results: 5/6 subtotal nephrectomy induced an increased of serum creatinine level in SN7 and SN28 (p<0,01 vs 
SO), followed by an increased of tubular injury score in SN7 and SN28 (p<0,01 vs SO). We confirmed reduction 
of nephrin expression in SN28 (p<0.01 vs SO). There was a negative correlation between nephrin and tubular 
injury (r=0.719, p<0.01) and the positive correlation between tubular injury and serum creatinine level (r=0.891, 
p<0.01). However, we did not find any significant correlation between nephrin expression and serum creatinine 
level.  
Conclusion: 
Nephrin expression downregulation might represent renal function disturbtion in CKD.   
 
Keywords: nephrin, 5/6 subtotal nephrectomy, remnant kidney, mice, serum creatinine, tubular injury, Sham 
Operation. 
 
Correspondence: Nur Arfian, raduate Student of Master in Biomediacl Science, Faculty of Medicine, Public Health, and 





Kidney failure enhances the decrement of the renal function and marked by the reduction 
of Glomerular Filtration Rate (GFR). This alteration was followed by reduction of nephron 
significantly[1]. Indonesian nephrologist association declared from 2007 until 2012, there is an 
increase of the new patients who used hemodialyzer, and it reaches 28.782[2]. 
The 5/6 subtotal nephrectomy (remnant kidney model) has been widely used as a 
pathogenic mechanism of chronic kidney disease and has been reliance on studies of renal 
diseases’ progressivity. The remnant kidney model is performed by unilateral nephrectomy and 
followed by contralateral renal ablation. Hypertrophy and hyperplasia are the hallmarks of the 
remnant kidney model. Shortly, after performing renal contralateral renal ablation various 
changes develop [3]. Remnant kidney model demonstrates the histopathological features, for 
example: decreased of podocyte density, segmental proliferation of parietal epithelial cell, 
tubule cell reflux, and lost of brush border at proximal tubules [4]. 
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Podocyte integrity is maintained by nephrin. Nephrin is located in the slit diaphragm of 
podocyte specifically [5]. Renal tubules cells destruction is caused by excessive inflammation 
process that which lead into tissue edema & tubules cells injury, tubule blood circulation 
distubances, direct contact with toxic agents like drugs, radiocontrast agents, myoglobin, 
radiation, or tubules obstruction that are caused by casts, cellular debris, or crystal 
sedimentation [6]. Until now, nephrin role toward kidney disease are not well understood. So, 
this research purpose is to elucidate the correlation between nephrin, creatinine serum level, 
and renal tubular injury in kidney-failure-model-mice with 5/6 subtotal nephrectomy. 
 
MATERIALS AND METHODS 
 
Preparation of Experimental Animal 
We obtained the animals from Unit Pengembangan Hewan Penelitian (UPHP), 
Universitas Gadjah Mada. We performed quasi-experimental research using 24 male Swiss 
background mice, 4 months-old (30-40 grams). The mice were divided into 3 groups: (1) SO 
(Sham Operation) group; (2) SN7 (7 days post-subtotal nephrectomy) group; (3) SN28 (28 
days post-subtotal nephrectomy) group. Mice were maintained in the Anatomy Laboratorium, 
Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada in the temperature 
21C, 50-60% humidity, and 12 hours light: dark cycle. Mice were fed with standard chows 
and water ad libitum.  
 
5/6 Subtotal Nephrectomy (SN) procedure  
We performed the SN procedure in two days. The first day, we anesthetized the mice 
with intraperitoneal injection of 0,1mL/10grams Body Weight (BW) of sodium pentobarbital. 
We opened right Flank’s region, visualized the kidney, then removed the renal capsule and cut 
the kidney after renal pedicle ligation (uninephrectomy procedure). In day 2, we did the same 
procedure for the left kidney, however, we ablated the superior and inferior poles of the left 
kidney. Bleeding was stopped with electro cauter of the kidney. Mice were kept alive and 
sacrificed in day7 (SN7 group) and day28 (SN28 group). We committed the same procedure 
as the SN group without any removing kidney for Sham Operation (SO) group.  
 
Serum Creatinine Level 
After the due date, the blood was taken from the retro-orbital vein. Afterwards, we 
obtained the serum through centrifugation at 10.000 rpm for 10 minutes. The creatinine level 
was assessed in the clinical pathology laboratory, Faculty of Medicine, Public Health, and 
Nusing, Universitas Gadjah Mada.  
 
Kidney harvesting 
Termination was carried out with euthanasia procedure using lethal dose of ketamine. 
Then mice were dissected and perfused with NaCl 0.9% through apex cordis. To reduce the 
intracardiac pressure, we opened the right atrium. The kidney was harvested then put into RNA 
Later for assessing mRNA expression and fixated the kidney in 4% paraformaldehyde for 
histological examination.  
 
Histopathological Quantification 
Four micrometers of the tissues were cut and stained with Periodic Acid-Schiff (PAS) in 
Pathological anatomy Laboratory. This staining was performed in order to assess tubular 
injury. Quantification of tubular injury was performed under microscope using 400x 
magnification. We captured 10–15 random fields for quantification of tubular injury score.  
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Tubular injury score was assessed based on histopathological changes such as tubular 
dilatation, brush border loss, tubular atrophy, nucleus condensation, intraluminal cast, and 
leukocyte infiltration [7]. Each slide was assessed based on the criteria and divided into score 0 
until score 4. Score 0 was given if there is no changing at all (normal), score 1 if there were 
tubules destruction less than 25%, score 2 if there are tubules destruction between 25 until 50%, 
score 3 if there are tubules destruction between 50 until 75%, and score 4 if there are tubules 
destruction more than 75%. Tubular injury score quantification was performed by 3 slide-
observers that blinded, then we made average tubular injury score  from 3 observers. 
 
Nephrin mRNA Expression 
Nephrin mRNA expression was examined using Reverse Transcriptase-Polymerase 
Chain Reaction (RT-PCR). Afterwards, we performed densitometry analysis to analyze 
nephrin band intensity using ImageJ software with GAPDH as house-keeping gene. As much 
as 3 µL cDNA was used for RT-PCR with addition of these following reagents: (Primers, 
dNTP, 10×ExTaq buffer, enzyme). We prepared RT-PCR mixture for each cDNA that consist 
of: forward primer Nephrin 0,6 µL; reverse primer Nephrin 0,6 µL; PCR water 8,3 µL; Taq 
master mix 12,5 µL (last added). The condition for RT-PCR are denaturation step for 10 second 
at 940C, annealing step for 20 second at 600C, extension step for 1 minutes at 720C with 35 
cycles. The amplicon was kept in 40C. Nephrin expression intensity was analized using ImageJ 
software. Analysis score was compared with GADPH expression intensity, so we earned the 




Creatinine serum level in SO group were 0.74 mg/dL; SN7 group 1.28 mg/dL; and SN28 
group 1.48 mg/dL respectively. There  was significant difference between SO group vs SN7, 
SO vs SN28, dan SN7 vs SN28 (p<0.01). Tubular injury score in SO group was 0.522; SN7 
group 2.04; dan SN28 group 3.28 (Fig. 1). There was significant difference between SO vs 
SN7 and SO vs SN28 (p< 0.01). There was significant difference between SN7 vs SN28 (P< 
0.05). Nephrin mRNA expression was significantly different between SO group and SN28 
group. The SN28 group had lower Nephrin mRNA expression (p<0.01) compared to SO and 
SN7 group (p< 0.05). There high significant positive correlation between tubular injury and 
creatinine serum level. There was intermediate no-significant negative correlation between 
nephrin expression and serum creatinine level. There was  high significant negative correlation 










Figure 1. Histopathological tubular injury. (A) Tubular injury in SO group. (B) Tubular injury 
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Figure 3. Correlation. (A) Tubular Injury with Serum Creatinine. (B) Expression of Nephrine 
with Serum Creatinine. (C) Expression of Nephrine with Tubular injury. 
 
Table 1. Average ± standard deviation of serum creatinine level, tubular injury score, and 
nephrin expression in each treatment group 
Group 
Average ± Standard Deviation 
Nephrin 
expression 
Tubular injury score 
Serum creatinine 
level 
A (SO) 0.1103 ± 0.019 0.5222 ± 0.1838 0.74 ± 0.089 
B (5/6 SN 7 days) 0.1026 ± 0.015 2.0445 ± 0.4305** 1.28 ± 0.109** 
C (5/6 SN 28 
days) 
0.0640 ± 0.0138** 3.2858 ± 0.3074** 1.48 ± 0.083** 




Remnant kidney model induces CKD after 7 days and 28 days with diffrerent degree 
severity. Chronic kidney failure was confirmed through augmentation of serum creatinine level 
followed by increasing tubular injury score. Nephrin expression was significantly decreased in 
SO group with SN28 group and SN7 group with SN28 group. There was significant negative 
correlation between nephrin expression and tubular injury score. The 5/6 Subtotal nephrectomy 
stimulates the development of the hypertrophy and hyperplasia of nephron as the compensation 
of decrement renal function [8,9,10]. It followed by histopathological changes which is shown as 
glomerulosclerosis, tubulointerstitial injury, renal dysfunction, and the most dangerous is 
uremic syndrome can occured in mice with 5/6 subtotal nephrectomy [10,11]. There was strong 
negative correlation between tubulointerstitial destruction with renal function disturbance in 
some glomerular immune diseases like membranous nephropathy, mesangioproliferative 
glomerulonephritis, focal segmental glomerulosclerosis (FSGS), type 1 mesangiocapillar 
glomerulonephritis, lupus nephritis, and other glomerular non-immune diseases like diabetic 
nephropathy[3]. In this research, 5/6 subtotal nephrectomy in mice can induce the occurence of 
SO SN7 SN28 
Nephrin 
GADPH 
A B C 
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kidney failure that confirmed with increasing severity tubular injury and followed by 
decreasing nephrin expression due to longer treatment.  
Creatinine serum level is the gold standard to assess renal function and it affected by 
tubular secretion and production, and extrarenal elimination.[12]. Creatinine is excreted by 
kidney in fixed amount based on muscle mass and free in plasma protein, so it can be a marker 
to evaluate renal function[13]. Increasing serum creatinine level indicated there was reduction 
of Glomerular Filtration Rate (GFR)[14]. Creatinine serum level that assessed form 24-hours 
urine is fragile to the error occurence and tend to not practical[15]. Recommendation for 
creatinine is better using serum creatinine than clearance creatinine[16]. In this study, creatinine 
level measured using serum creatinine level. There are factors that can affect to GFR like ages, 
races, genders, and body sizes[16,17]. 
Creatinine serum used to assess renal function and affected by tubular secretions, 
production, and extrarenal elimination[12]. We quantified the increment of creatinine serum in 
order to confirm renal function in chronic kidney disease model, 5/6 subtotal nephrectomy. 
Quantification of increasing serum creatinine level was performed to confim the occurence of 
kidney failure[18]. Remnant kidney model leads to damage of histopathological architecture, 
such as decrease of podocyte density, segmental proliferation of parietal epithelial cell, tubular 
cell reflux and lost of brush border at proximal tubule [4]. 
Increase of creatinine was followed by epithelial tubular cells injury which marked by 
CD24-positive cells. It consists very least of cytoplasm, mitochondria, and lost of brush border 
[19]. Dilatation of tubules, lost of brush broder, vascular remodeling, detachment of cells from 
glomerular basement membrane, infiltration of leukocyte, and capillary edema were the 
characteristic of tubular injury [7] [20]. Tubular injury score was increase significantly in 5/6 
subtotal nephrectomy mice. Glomerulosclerosis may lead to tubular injury in kidney failure 
disease [21].  
Prolong chronic kidney disease reduced mRNA expression of Nephrine. Nephrine has an 
important role in maintain the integrity of the glomerular. Inactivation of the nephrine genes 
stimulates severe proteinureia. The alteration of the both mRNA and protein of Nephrine have 
an important role in pathological process of kidney disease. It affects glomerular membrane 
permeability [22]. Downregulation of the mRNA Nephrine expression followed by proteinuria 
and increase of creatinine was not significantly statistic (p>0.01). Since creatinine serum is the 
marker of glomerular injury. 
From the previous research, downregulation of nephrine expression was correlates to the 
progressivity of kidney disease. Progressivity of glomerular injury contributes to the 
development of tubular injury caused by glomerular injury. During glomerular injury, the 
integrity of glomerular basement membrane was imperfect. Consequently, the level of nephrine 
and the other podocyte cytoskeleon was altered. Here, we elucidated that the downregulation 
of nephrine followed by increase of tubular injury, but this alteration does not followed with 




Chronic kidney disease induces downregulation of the mRNA Nephrine expression and 
negatively correlate with the augmentation of tubular injury score. Meanwhile, the tubular 
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ABSTRACT 
Background: Exposure to ultraviolet B (UV-B) rays causes skin aging characterized   through increased free 
radical damaged. To prevent skin aging due to UV-B exposure, it is necessary to additionally provide antioxidants 
as a measure to inhibit the skin aging process. Bajakah tree (Spatholobus littoralis hassk) is one antioxidants 
sourche such as phenols, flavonoids, and tannins. The aim was to prove that the administration of Bajakah stem 
ethanol extract cream inhibits increasing MMP-1 expression and reduction of collagen number in male Wistar 
rats exposed to UV-B. 
Methods: A posttest control group study design was coducted in male rats (Rattus norvegicus), Wistar strain, 
aged 2-3 months, weigh 180-200gram which was divided randomly into two groups. The control group (n = 18) 
was exposed to UV-B rays and placebo  cream (0.2 mg/cm2), while the treatment group (n = 18) was exposed to 
UV-B rays and Bajakah stem ethanol extract cream 15 % (0.2 mg/cm2). Both creams have aplied twice before 
and after exposure to UV-B rays (3 times a week, with 840 mJ/cm2) for 4 weeks. Twenty-four hours after the last 
day intervention, a punch biopsy of skin tissue was prepared for histological examination followed by 
immunohistochemical assay (for MMP-1) and Sirius red (for collagen) staining. 
Results: The expression of MMP-1 was significantly higher in the control group (24.3 ± 6.20%) compared to the 
treatment group (11.5 ± 3.21%), p<0.001. Furthermore, the number of collagen was statistically lower in the 
control group (63.1 ± 3.94%) compared to the treatment group (82.0 ± 3.02%), p<0.001.  
Conclusion: The administration of bajakah (Spatholobus littoralis hassk) stem ethanol extract cream inhibited 
the increasing of MMP-1 expression and the reducing of collagen cells in male Wistar rats (Rattus norvegicus) 
those were exposed to UV- B. 
 
Keywords: Bajakah stem, MMP-1, collagen, ultraviolet B.  
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Indonesia is one of tropical countries with high sunlight intensity that can cause skin 
aging. Sunlight caused both acute  and chronic effects on the skin. In this current study, what 
was observed was chronic damage, namely photoaging. Inhibiting, preventing, and restoring 
the skin aging process can be done and is one of the focuses of Anti-Aging Medicine (AAM). 
Since ultra violet (UV) rays in sunlight exposure causes skin aging, efforts to prevent the 
development of the aging phenotype is one of the Anti-Aging Medicine.1 
Sunlight that caused photoaging is UV rays with a wavelength of 10 - 400 nm. Photoaging 
is characterized by an increase expression of matrix metalloproteinase (MMP).2 MMP-1 is the 
main collagenase increased by UV-B exposure. UV radiation induces MMP-1 expression by 
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dermal fibroblasts, partly stimulated by the formation of excess reactive oxygen species (ROS), 
and plays an important role in photoaging.3 MMP-1 together with its inhibitor, tissue inhibitor 
of metalloproteinases (TIMPs), plays a role in the fragmentation of types I and III collagen. 
The increasing MMP-1 due to UV-B resulted in the increasing collagen degradation, so that 
the amount of collagen decreases. The molecular mechanism of MMP-1 degrades collagen is 
by cutting the collagen fibers in the three alpha chains at one locus which is located around the 
first quarter of the N-terminal collagen chain and produces TCA and TCB fragments.4  
An increase of MMP-1 and be followed by a decrease of collagen are the main causes of 
skin aging due to exposure of UV-B rays; hence, it is necessary to make efforts to inhibit the 
increase in MMP-1 and the decrease of collagen as part of AAM. Many studies have been 
carried out using natural creams containing antioxidants and bioactive compounds to prevent 
photoaging. 
Recently, the stem of Bajakah tree (Spatholobus littoralis hassk), a plant that is growing 
in forest of Kalimantan island, has come to attention in Indonesia.5 Traditionally, this plant has 
been used orally or topically by the local community for curing some health problems.6 
Previously, research has shown qualitatively the presence of flavonoids, saponins, steroids, 
terpenoids, tannins, and phenols, and has been shown to accelerate the wound healing process.5  
Scientific research on the Bajakah plant is only limited to its qualitative content and its 
effect on the wound healing process.5 The content of active compounds and antioxidants have 
been widely reported to be able to prevent photoaging. The purpose of the study was to prove 
that the administration of Bajakah stem ethanol extract cream inhibits the increasing of MMP-




A post-test only control group design, with subjects male rats (Rattus norvegicus), Wistar 
strain, aged 2-3 months, weighing 180-200gram which were divided randomly into two groups. 
The control group (n = 18 rats) was exposed to UV-B rays and placebo cream (0.2 mg/cm2), 
while the treatment group (n = 18 rats) was exposed to UV-B rays and Bajakah stem ethanol 
extract cream 15 % (0.2 mg/cm2). The cream was administered 20 minutes before and 4 hours 
after exposure to UV-B rays (3 times a week, a total dose of 840 mJ/cm2), for four weeks. 
Twenty-four hours after the last day of intervention, a punch biopsy of skin tissue was prepared 
for histological examination followed by immunohistochemical assay (for MMP-1) and Sirius 




The expression of MMP-1 in the control group was (24.3 ± 6.20)% and the treatment 
group was (11.5 ± 3.21)%. The comparative analysis using the independent T-test showed a p-
value of <0.001 which indicates that there was a significant difference in MMP-1 expression 
higher in the control group compared to the treatment groups (pigure 3.(A)). In addition, the 
amount of collagen in the control group was (63.1 ± 3.94)% and the treatment group was (82.0 
± 3.02)%. Comparative analysis showed a p-value of <0.001 which indicates that there was a 
significant difference in the amount of collagen lower in the control group compared to the 
treatment groups. 
The Visual fiture shown in pigure 1, the experssion MMP-1 (brown color) in the control 
group (A, B) is higher than that in the treatment group (C, D). So do, the collagen fiture in 
pigure 2 shown that collagen of the control group (A, B) fragmented and tinner than that the 
collagen of the treatment group (C,D). 
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Figure 1. Expression of MMP1 examined by immunohistochemistry in Dermal Tissue 
 
A. Control group (100x magnification). 
B. Control group (400x magnification). The expression of MMP-1 (brown color) was higher compared to the 
treatment groups. Red arrows indicate fibroblast cells expressing MMP-1. Black arrows indicate fibroblast cells 
that did not express MMP-1 
C. Treatment group (100x Magnification) 
D. Treatment group (400x magnification). MMP-1 expression (brown color) was less than the control group. Red 
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Figure 2. Collagen in Dermal Tissue with Picro-Sirius Red Staining 
 
A. Control group (100x magnification). 
B. Control group (400x magnification). The structure of collagen with red collagen fibers appeared to disintegrate 
and thin. The black arrows indicate thick collagen fibers. Yellow arrows indicate thin collagen fibers. 
C. Treatment group (100x Magnification). 
D. Treatment group (400x enlargement). The collagen structure was more intact and thick than that of the control 
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Figure 3. The Comparison of (A) MMP-1 Expressions (%) and (B) Collagen number 
(%) between Control and Treatment Groups 
 
DISCUSSION 
Recently, the Bajakah plant (Spatholobus littoralis hassk) receives a lot of attention in 
Indonesia because of its potential to inhibit the growth of cancer cells.5 In addition, this plant 
has been widely used traditionally, for some health problem.6 However, the current study is the 
first to demonstrate the potential of the ethanol extract of the stem of bajakah for preventing 
aging process, particularly for skin aging caused by exposure to UV-B rays. 
 Anti-Aging Medicine (AAM) aims to maintain health regardless of chronological age 
i.e. to stay healthy and biologically efficient. AAM aims to treat the causes of aging that 
underlie the aging process and to reduce all age-related diseases.1 One aspect of aging that 
many people focus on is skin aging. By knowing the etiology and pathophysiology of skin 
aging, efforts can be made to prevent this skin aging process. 
Previously, research has shown qualitatively the presence of flavonoids, saponins, 
steroids, terpenoids, tannins, and phenols, and has been shown to accelerate the wound healing 
process in mice.5 These results were then confirmed through the results in this study, showing 
that the phytochemical content of the Bajakah stem extract were flavonoids, phenols, tannins, 
and antioxidant capacity. Each of these active compounds contained in the Bajakah stem 
ethanol extract has their respective contributions and roles in inhibiting the increase in MMP-
1 expression and decreasing the amount of collagen.  
Polyphenols have a photoprotective effect on oral and topical administration through their 
antioxidant abilities.8  As antioxidants, phenolic compounds remain stable and do not 
experience resonance after donating atoms in radical compounds, thus stopping chain reactions 
caused by other radicals.9 Because UV-B radiation increases the production of ROS which then 
activates MAPK and forms complex with the transcription factor AP-1, which plays an 
important role in the regulation of MMP-1 transcription which then results in collagen 
degradation.10 Hence, polyphenols in the ethanol extract of the Bajakah stem which are 
antioxidants can neutralize the production of ROS due to UV-B and there is no increase in 
MMP-1 expression, and collagen degradation is also inhibited. 
Research has reported that flavonoids can suppress MMP-1 expression and induce 
expression of procollagen type I protein in UV-induced cell culture.11 Flavonoids also inhibit 
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the activation of nuclear factor kappa B (NFkB), which is a transcription factor for MMP-1 so 
that MMP-1 levels decrease and collagen degradation does not occur.12  
Research has shown that tannins can interact with collagen through hydrogen bonds and 
hydrophobic interactions thereby increasing the thermal stability and enzymatic stability of 
collagen. Tannins can increase the hydrothermal stability of collagen and inhibit collagen 
degradation by MMP-1 through the formation of hydrogen bonds and hydrophobic 
interactions. Tannins also bind to collagen with high affinity because the structural flexibility 
of collagen compensates for the structural rigidity of phenolics.13  
To date, many studies have been carried out using natural ingredients creams that contain 
antioxidants and bioactive compounds to prevent photoaging. This is because Indonesia has 
vast natural resources that are easily available and relatively cheap. In addition, natural 
compounds are relatively safer to use (relatively lower toxicity) than synthetic chemicals. 
This research was conducted because we believed that the Bajakah stem extract had better 
potency than other plant extracts that had been studied previously. Bajakah stem extract cream 
contains phytochemical compounds and antioxidants that are better than other plants. The 
extract of the Bajakah stem used in this study had flavonoid content (79739.70 mg/100gQE), 
total phenol (14952.12 mg/100gGAE), tannins (17920.42 mg/100gTAE), antioxidant capacity 
(63141.06 mg/L ) and Inhibitory Concentration (IC) 50% (13.25 mg/L). 
Whereas previous research using cherry leaf extract cream (Muntingia calabura Linn) 
contained a total phenol of 2352.77 mg/100gGAE, flavonoids of 1765.34 mg/100gQE, tannins 
of 289.50 mg/100gTAE, antioxidants of 7563.90 mg/L GAEAC, and IC50% of 53.18 ppm 
were sufficient to inhibit the increase in MMP-1 expression and decrease the amount of 
collagen in the skin of male Wistar rats exposed to ultraviolet B rays.14 The Lepisanthes 
amoena leaf extract containing flavonoids (986.62 mg/100gQE), antioxidant capacity 
(135627.21 mg/L), and IC50% (101.25 mg / L) can inhibit the increase in MMP-1 and decrease 
the amount of collagen in male Wistar rats exposed to UV-B rays.15  
Based on the comparison of these bioactive compounds, it can be concluded that the 
Bajakah stem extract cream is potentially better for use as an Anti-Aging Medicine, especially 
skin aging caused by exposure to UV-B rays. 
Excessive UV-B exposure is the main etiology of skin aging especially in tropical 
countries like Indonesia. Meanwhile, an increase in MMP-1 and a decrease in the amount of 
collagen is pathophysiology of skin aging due to exposure to UV-B rays. So that in relation to 
AAM it is necessary to make efforts to inhibit the increase in MMP-1 and decrease the amount 
of collagen. Bajakah stem ethanol extract cream is one of the Anti-Aging Medicine steps 




The administration of Bajakah (Spatholobus littoralis hassk) stem ethanol extract cream 
inhibited increasing MMP-1 expression and the reduction of collagen in male Wistar rats 
(Rattus norvegicus) exposed to ultraviolet B. Next, it is necessary to perform a comparative 
study of the Bajakah stem cream with creams of other plant extracts with the same content to 
prove that natural ingredients are the best anti-aging modality for the skin. However, the toxic 
potential for long-term topical use ethanol extract of the Bajakah stem has never been reported; 
thus, further study is necessary. Clinical research in humans is also warranted before it can be 
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ABSTRACT 
For several decades ago, passive immunization has already proven its ability to treat some diseases, especially 
pandemic diseases. On the contrary, after antibiotics discovery, the usage of passive immunization becomes 
neglected. Nowadays, we face a pandemic situation, COVID-19, which needs the possible treatment to save 
patients lives while medicines and vaccines are under development. By learning from history, passive 
immunization seems to be the best choice to save patient lives. As a kind of passive immunization, antibody-based 
therapy successfully treats diseases, including infectious diseases. Several antibody-based therapies are 
developed, as vast as the technology development, especially after the genetic codes announced. This article 
highlighted the influence of genomics tools, which helps researchers develop various platforms in developing 
monoclonal antibodies with high safety and efficiency in production and application.    
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Disease prevention and treatment efforts, especially treatment, have developed so rapidly 
that various treatment models based on herbs, synthetic compounds, vaccines, and 
immunotherapy. Immunotherapy is conducted by providing an agent that eliminates pathogens 
without activating the body's immune system. In general, immunotherapy is carried out by 
delivering immune system components into the body of individuals1,2One of the 
immunotherapy is antibody-based therapy or passive immunization. Passive immunization is 
an immunotherapy method performed by providing antibody neutralization into the body of 
the individual3 
At the time of an outbreak of the disease, passive immunization becomes the most viable 
treatment method to be applied. At present, when FDA approved one of passive immunization, 
convalescent plasma, to treat COVID-19 patients with severe symptoms. The approach used to 
surpress the increasing number of mortality rate caused by the infection of SARS-CoV-2 
(FDA)4. Treatment with convalescent plasma, which introduced in 1890s by Kitasato and von 
Behring could eliminate pathogen by neutralizing antibodies provides by convalescent plasma. 
However, there are several limitations for convalescence plasma, such as difficulties in finding 
the people who proper to become a donor, the volume of antibodies delivered to the recipient, 
and antibodies purification to separate antibodies from blood cloths5. 
To overcome the weakness of convalescent plasma, monoclonal antibodies (mAbs) 
become an option to save patients’ lives. At the past, mAbs developed by fusing immortal cells 
with splenocytes from immunized mice. Nowadays, the big data of sequence information 
available on the DNA libraries provide a new wave on antibody-based therapy. By using 
machine learning, antibody therapeutics are developed as humanization and synthetic 
monoclonal antibody which called engineered antibody6. This review will discuss the kinds of 
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This article used systematic review according to guidance provided on PRISMA 2009.  
 
Objectives 
To find out the role of artificial intelligence in the development of antibody-based therapy for 
COVID-19. 
 
The Strategy of Literature Searching and Selection 
Literatures were searched on January 20th 2021 by using two kinds of electronic database, 
PubMed and SCOPUS, with keywords "artificial intelligence" AND "antibody", "antibody-
based therapy", "immunoinformatics" AND “antibody”, "engineered antibody" and “COVID-
19” AND “monoclonal antibodies”. We limit the articles which only articles written in English 
and published in 2019 until 2021. For collecting the articles, we did not restrict to specific type 
of articles. We sorted the articles to find out the redundancy possibility by filtering the title. 
We put several specifications which differ as inclusion and exclusion criteria. All articles for 
this review were research articles which develop monoclonal antibody using artificial 
intelligence as part of methods to treat COVID-19. We excluded research articles which related 

























Figure 1. Process of literature searching and selection according PRISMA 
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A total of 2504 articles obtained from two journal repositories, but only 70% were single 
articles. After screening the title and abstract only 172 articles related to artificial intelligence 
in the development of therapeutic antibodies for COVID-19, only 36 articles are research 
articles. Among the selected articles, only 1 study used only experiments in silico and 17 
articles using in vivo experiments to determine the effectiveness of antibodies developed 
(Table 1). The majority of studies report using cloning strategies and protein expression by 
mammalian cells, though just two studies use a plant as their expression system, Nicotiana 
benthamina, to produce antibodies (Table 2).   
 
Table 1. Development humanized antibody for therapy 
Ref Experiment Animal model 











Alsoussi7 Y Y Y C57BL/6J mice 






Hansen8 Y Y Y VelocImmune® 
(VI) mice  
RBD Antibody cocktail 
(REGN10933+REGN10987) 
Brett9 Y Y N N Spike  
Chi10 Y Y N N Extracellular 
domain of S 
protein 
4A8 
Custódio11 Y Y N N RBD Sb23 
Dong12 Y Y N N RBD 9 VHH-Fc 
Ejemel13 Y Y N N RBD mAb362 
Fagre14 Y Y Y Syrian Hamster RBD AvGn-B 
Hassan15 Y Y Y BALB/c mice; 
C57BL/6J; 
DBA2/J 
S protein 1B07 and 2F05 
Huo16 Y Y N N RBD CR3022 





Kreye18 Y Y Y C57BL/6J mice; 
hamster 
RBD CV07-209 
Li19 Y Y Y BALB/c mice; 
C3B6 mice 
RBD Ab1 
Liu20 Y Y Y Hamster RBD 2-15 mAb 
Lv21 Y Y Y a humanized 
hACE2  
C57BL/6  mice 
RBD H014 Fab fragment  
Miao22 Y Y N N RBD 89C8-ACE2 
Noy-Porat23 Y Y N N RBD MD62 and MD65 
Parzych24 Y Y N N RBD; IL-6R anti-CR3022 dmAb; Anti-IL-
6R dmAb 
Piccoli25 Y Y N N RBD None 
Pinto26 Y Y N N spike S309 
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Ref Experiment Animal model 











Premkumar27 Y Y N N RBD 
 
Rattanapisit28 Y Y N N RBD CR3022 
Rogers29 Y Y Y Syrian Hamster Spike CC12.1 mAb  





C104 shows Fc effector 
function 
Seydoux31 Y Y N N RBD CV30 
Shah32 Y N N N RBD in silico study for mutation on 
RBD influence mAb 
interaction 
Shanmugaraj33 N Y N N RBD B38; H4 
Shi34 Y Y Y Macaques RBD; ACE2 CB6 
Sun35 Y Y N N RBD region 2 VH-Fc (ab6 and m397) 
could bind to RBD 
Tai36 Y Y N N RBD None 
Wan37 Y Y N N RBD 11 mAb 
Wang38 Y Y Y Rhesus 
Monkeys 
RBD MW05 




Zhang40 Y Y Y Balb/c  RBD 2H2/3C1 
Zost41 Y Y Y Balb/c, 
Macaques 
Spike cov2-2196; cov2-2130 
Zost42 Y Y N N RBD COV2-2130 
Zylbermann43 Y N Y Horse RBD F(ab')2 pAb 
 
Table 2. Utilization on Artificial Intelligence (AI) 
 
Ref Source of 
Antibody 































constant region  
HEK293T cells 
(for Ag); CHO 
cells (for mAb) 
Brett9 Synthetic 
antibody 
Y Y VSV N, P, 
L and G 
expression 
plasmids 
pCAGGS HEK293T cells 
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Ref Source of 
Antibody 









Y Y pCAG 
vector  
pcDNA3.4  HEK 293F (for 
Ag); Expi293F 
cells (for mAb) 
Custódio11 synthetic 
antibodies 







NM Y NM NM NM 
Ejemel13 Humanize
d mice 
Y Y pcDNA 3.1 
Myc/His  
Immunoglobuli













heavy chain and 































 Sf9 cells (for 
Ag); ExpiCHO 

















Y Y  pCAGGS  a phage-display 
scFv  
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Ref Source of 
Antibody 































Y N pαH  
 
Expi293 cells 





y Y phCMV3  expression 
vectors 
encoding the 
human IgG1, Ig 




cells (Ag); DH5 
alpha (mAB) 
Schafer31 N Y Y pNL4-3-
nanoluc and 
lentiviral  
Ig heavy and 
light chain 
expression 










Shah33 N Y Y N N n 
Shanmugaraj3
4 









N Hi5 cells 
























y y pEt21 n 
pFastBac1, 
pEGFP-N1  






Y Y N pcDNA3.4 ExpiCHO cells 
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Ref Source of 
Antibody 





















The discovery of antibody utilization for Kitasato and von Behring treatment in 1870 
elicits people to employ antibodies to treat disease. The employment of human plasma as the 
source of antibodies to treat patients was started in 1907. Nowadays, it is known as 
convalescence plasma therapy5,44. The use of convalescent plasma later turned into intravenous 
immunoglobulin (IvIg) after Cohn's antibody separation method and the team in the 1940s 
(figure 1). 
Due to several requirements must be fulfilled by potential donors and also the number of 
donors to obtain enough antibodies become the obstacles to apply convalescence plasma as a 
routine therapy. On the other side, there is a demand for antibodies to treat diseases due to their 
ability to identify specific pathogens. The discovery of hybridoma technology in the production 




Figure 2. Timeline of antibody-based therapy  
 
The hybridoma technology produces monoclonal antibodies from immortal cells known 
as hybridoma cells. However, another problem arises due to the patient's immune reaction to 
the antibodies given, namely the rejection of antibodies which occurs by the formation of 
HAMA (Human anti-mouse antibody. Two antibody production methods are developed to 
overcome the problem45–48. The first method uses hybridoma technology using human B 
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Figure 3. Development of therapy using antibodies. A. Production of antibodies with 
convalescent plasma method. B. Production of the antibody with the 
hybridoma method. C. Production of humanized antibody from peripheral 
blood mononuclear cells. Figure created by biorender.com.  
 
Plasma Therapy for Covid-19 
Convalescent plasma therapy has been used as one of medications for some outbreak 
diseases such as SARS (2003), avian influenza H5N1 (2005-2015), avian influenza H1N1 
(2009-2010), and ebola (2013-2015).  At present, the therapy becomes the potential therapy to 
cure COVID-19 patients, although the appliance must be done under supervision from EUA49 
Several studies have reported the effects of convalescent plasma administration in patients who 
have severe and critical symptoms. 
Li et al. (2020) has reported that patients who get plasma therapy show some 
improvement. In the group of patients who received plasma therapy (n = 52), only 28.6% of 
patients who died were lower than the other group. Furthermore, the virus clearance is more 
effective by administering plasma therapy which is confirmed by PCR and shows that it is not 
detected the presence of viruses that cause COVID-19 from 24 hours to 72 hours after therapy 
with a 1x24-hour examination interval50. 
Shen (2020) reported his research results on 5 COVID-19 patients who were not smokers 
and received ventilators during treatment. The study reported that three patients did not use 
ventilators after plasma administration while the other two patients had been released from 
ecmo-type ventilators (extra-corporeal membrane oxygenation). In addition, the CT scores of 
the five patients also reached negative with a range of 1-12 days after convalescent plasma 
therapy. Similar result also reported by Duan et al who stated that plasma therapy improved 
the lung condition of patients indicated by the changing in the type of ventilator51 
The positive effects of plasma administration in patients with severe and critical symptom 
criteria were also reported by Zeng et al and Duan et al52,53. Zeng et al. conducted the research 
by providing plasma therapy to 6 critical patients. The study reported that 5 out of 6 patients 
had negative CT scores but died, but the five patients' length of life was longer compared to 
patients in the group of patients who did not get plasma therapy. This study shows that plasma 
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therapy can improve the patient's immune system.  Research conducted by Duan et al. reported 
that the administration of plasma convalescence could improve the patient's lung condition, 
and there is an elimination of the virus characterized by an increase in CT value until it is 
indicated negatively on the third or sixth day after convalescence plasma administration52,53. 
Human antibodies for therapeutic purposes can be developed with two approaches: 
hybridoma technology and genetic engineering divided into four platforms: hybrid mouse, 
phage display, transgenic mouse single B cell (figure 4)54. Both approaches require the 
involvement of artificial intelligence that can process genetic data into a monoclonal antibody. 
This artificial intelligence is used to design antigens used in hybridoma technology and design 










Figure 4. Development of antibody for therapy (cited from Lu et al.54) 
 
With hybridoma technology, specific antibodies can be obtained by stimulating the 
immune response to a particular antigen and a particular epitope. Meanwhile, with genetic 
engineering, antibodies can be produced using genetic information that develops antibodies' 
structure and is expressed by an expression system. Furthermore, the merging of mice and 
human antibodies are possible to be produced by engineered antibodies (recombinant 
antibodies). It is an urge to use bioinformatics tools to develop recombinant antibodies. The 
bioinformatics also applied to predict the promiscuous epitopes that can be conducted by 
immunoinformatics 55–57. By applying bioinformatics, the structure of antibodies, antigen, and 
antigen-antibody interaction could be visualized by molecuar docking and molecular 
modelling. 
Based on the selected literature, there are two strategies to develop antibodies for therapy 
in SARS-CoV-2 infection. The first strategy is designing antigens to stimulate the formation 
of specific antibodies, and the second is by designing human monoclonal antibodies (tables 1 
and 2). The in vivo experiments have been conducted to trial the antibodies by using several 
animal models, namely Llama, horses, and mice8. 
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Antigen design for the development of human antibodies with hybridoma technology 
Antigen with high functionality is vital in producing antibodies through hybridoma 
technology. Due to the formation of antibodies requires cooperation between APC cells and T 
lymphocyte cells to stimulate B cells to release antibodies. With machine learning, the antigen 
is designed to interact with T and B cells that predicted or determined by various software for 
mapping epitopes. A wide range of epitope mapping immunoinformatics software can be used 
either through web servers or installed software. 
The development of SARS-CoV-2 antigens to produce specific proteins was carried out 
using genetically engineered technology to produce both S and RBD proteins from the SARS-
CoV-2 virus. Spike and RBD proteins chose because those proteins have an important role in 
the mechanism of viral infection in the host cell 57. SARS-CoV-2 virus infects humans by 
binding to human angiotensin-converting enzyme 2 (ACE2) on the cell surface with RBD 
region on S protein. The binding of RBD to ACE-2 is the main key to the process of viral 
infection into the cells58. 
In developing antibodies for COVID-19 therapy, the artficial intelligence plays a role in 
antigen design from protein selection and predicting the interaction between epitopes with B 
cells and T cells with molecular dynamic and molecular docking 55 (figure 5). This method is 
commonly used in vaccine development, but it also used to design an antigen for developing 
antibody therapy59. 
The application of molecular dynamics and molecular docking as a machine learning 
provides a very beneficial effect for antigen design because it can provide an overview of the 
structure and model of the designed antigen. Both machine learning will provide good 
visualization by merging other methods such as electron microscope and small angle X-ray 
scattering (SAXS)9. In a study conducted by Brett et al (2020), the structure of an endogenous 
glycoprotein G found in a VSV particle can be compared in size with the SARS-CoV-2 virus 
S protein designed in the same VSV particle 9. Other researchers used machine learning to 






















Figure 5. Schematic design of antigen by in silico experiment 
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Artificial intelligence also provides another benefit to developing antibody therapy, such 
as designing the antigen and interaction prediction only with a computational-based study. 
Shah et al. (2020) conducted antigen and antibody design research just using in silico 
experiment. This study was conducted to determine the interaction of CR3022 and CR3014 
antibodies with both the overall spike protein and RBD area with confirmation analysis and 
analysis of ligand interaction fingerprints (PLIF) proteins. The study also provides an overview 
of the 3-dimensional structure of spike proteins and RBD regions 32. 
 
Human antibody design with recombinant technology 
At the beginning of its development, there are three kinds of recombinant antibodies, 
namely chimeric antibody, humanized antibody and fully human antibody (Figure 4). Those 
three antibodies developed to minimize the rejection of patients who receive therapy 
Antibodies. On chimeric antibody, modifications are made on the constant domain of 
antibodies with maintains the territory of fragment antigen binding (Fab) derived from animals. 
Then chimeric antibody developed into humanized antibody conducted by inserting the 
animal's complementary-determining region (CDR) into the antibody sequence with CDR 
grafting technology and subsequently developed into a fully human antibody.  Fully human 
antibody provides an auspicious opportunity for treatment with antibodies, but these antibodies 
can still cause rejection reactions from patients, so two antibody formats are developed, 
fragment antigen binding (Fab) and single chain fragment variable (ScFv) (Figure 5).6,47 
 
 
Figure 5. Types of recombinant antibodies (cited from Kuhn et al.47) 
 
The development of artificial intelligence has a very significant effect on the process of 
antibody development. In the first beginning, the antibody was employed using recombinant 
technology and followed by in vitro and in vivo experiments, which were performed by 
histology and statistics. Currently, the binding position of antibodies designed on antigen 
targets can be visualized using various machine learning (Figure 6). In developing antibody 
therapy for COVID-19, scientists not only used viral proteins as the antigen, but receptors 
(ACE-2) were also possible to be designed as antigens. Scientists used various mammalian 
cells to express ACE-2, such as CHO (Chinese Hamster Ovarian) and HEK (human embryonic 
kidney) cells (Table 2).    
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Figure 6. Schematic design of antibody development using artificial intelligence 
 
The employment of machine learning has made it easier for researchers to get accurate 
information about antigens' interaction with antibodies designed. Besides, the information can 
be used by researchers to provide an explanation of its effects. Chi et al (2020) use cryo-EM to 
determine the interaction between the antibodies that have been designed (4A8) to the SARS-
CoV-2 virus S-ECD antigen. The results of their study stated that the designed monoclonal 
antibodies have an excellent neutralization effect which is not caused by interruptions in the 
binding of RBD with ACE2. The molecullar modelling shows that neutralization is likely to 




Antibodies for therapeutic for COVID-19 have been utilized by artificial intelligence. It 
took parts in antigen and antibody design. Moreover, the visualization of antibody structures is 
one of the results from data processing using machine learning adopted to predict the 
neutralization effect by antibodies from research in vitro and in vivo. The utilization of artificial 
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ABSTRACT 
Background; Glucose is the main energy source for cells. To be utilized by cells, glucose enters the intracellular 
space facilitated by transporters. GLUT1 is one of the glucose transporters and is the most widely expressed by 
various tissues in the body. Not only that, cancer cells, which are known to have very high glucose requirements 
compared to healthy cells, have a high expression of GLUT1 as well. 
Reviews; This paper reviews the structure, function, and biomedical importance of GLUT1 and specifically 
describes recent developments regarding GLUT1 inhibition as a novel therapeutic approach in both metabolic 
diseases and cancers. 
Conclusion; Inhibition of GLUT1 has also been shown to increase cancer cells' sensitivity to chemotherapy agents 
such as cisplatin and adriamycin. GLUT1 inhibition also increases the sensitivity of cancer cells to radiotherapy. 
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Glucose is the main energy source for eukaryotic organisms, which plays an important 
role in metabolism and cellular homeostasis. Catabolism of glucose through glycolysis, the 
citric acid cycle, and oxidative phosphorylation will produce energy in the form of adenosine-
5-triphosphate (ATP). Glucose also functions as an important raw material for synthesizing the 
main cell biomolecules, such as lipids, non-essential amino acids, and nucleic acids. In humans 
and animals that are breastfeeding, glucose plays an important role in synthesizing lactose in 
the mammary glands, which is the main carbohydrate in milk.1,2 
Glucose is mainly obtained directly from the diet through the enzymatic hydrolysis of 
disaccharides and polysaccharides in the digestive tract. Under certain physiological 
conditions, glucose can be synthesized by organs in the body such as the liver through the 
breakdown of glycogen (glycogenolysis) and the synthesis of glucose from non-carbohydrate 
substrates, namely pyruvate, lactate, glycerol, and glucogenic amino acids (gluconeogenesis).3 
Brain and red blood cells require a continuous supply of glucose. Meanwhile, most of the 
cells in the body need glucose in moderation. An increase in the concentration of glucose in 
the plasma can cause glucose poisoning (glucotoxicity). Therefore, the concentration of 
glucose in plasma is maintained in the range of 60-110 mg/dL and involves the role of 
metabolic hormones, especially insulin and glucagon. Glucose homeostasis in the body is 
maintained through coordinated regulation of three processes: 1) absorption of glucose as a 
result of the enzymatic hydrolysis of carbohydrates from food by the small intestine; 2) glucose 
production by body organs, especially the liver; 3) consumption of glucose by almost all body 
tissues.1 The discussion of this paper will further focus on the third regulatory process. 
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The glucose concentration is maintained over a narrow range by the homeostatic 
mechanism, as mentioned above, so that most cells obtain glucose from the interstitial fluid 
passively down the concentration gradient across the plasma membrane.2 Meanwhile, 
eukaryotic cells' plasma membrane (lipid bilayer) itself is impermeable to hydrophilic polar 
molecules such as glucose. Thus, to facilitate the entry and exit of glucose into and from the 
cell, an integral membrane protein called the glucose transporter is required.1,4 The exception 
is the brush border epithelial cells of the small intestine and the proximal renal tubule, where 
glucose is absorbed against the electrochemical gradient through a pump's secondary active 
transport mechanism. Na+/K+/ATP.2 This also shows that the expression of glucose transporters 
is tissue-specific, and this expression reflects each tissue's physiological characteristics.4 
Glucose transporter proteins fall into two distinct groups, structurally and functionally. 
The first group is the Na+-dependent glucose cotransporter, an active glucose transport 
mechanism for glucose absorption in the small intestine and glucose reabsorption in the urinary 
tract system. As the name implies, sodium-dependent glucose transporter, this protein group is 
given the SGLT symbol, and its coding genes are included in the solute carrier gene group 
(SLC) as the solute carrier family 5A (SLC5A). The second group is glucose transporters that 
are not dependent on sodium (Na+). This group transports glucose passively across the plasma 
membrane by a facilitated diffusion mechanism. The protein symbol for this second group is 
GLUT, which stands for glucose transporter. The gene encodes this protein belongs to the 
solute carrier family, SLC2A.2,3,4,5  
The human body has three types of glucose transporter that different in structure and 
transport mechanism. The first type is the Na+-dependent glucose cotransporter, an active 
glucose transport mechanism for glucose absorption in the small intestine and glucose 
reabsorption in the urinary tract system. As the name implies, sodium-dependent glucose 
transporter, this protein group is given the SGLT symbol, and its coding gene is included in the 
solute carrier gene group (SLC) as the solute carrier family 5A (SLC5A). The second type is a 
glucose transporter that is not dependent on sodium (Na+). This transporter transports glucose 
passively across the plasma membrane by a facilitated diffusion mechanism. The protein 
symbol for this second group is GLUT, which stands for glucose transporter. The gene 
encoding belongs to the solute carrier family, SLC2A. The third type, SWEETs, is a recently 




This article will further elaborate on the structure, function, characteristics, and 
biomedical interests of GLUT1 as a glucose transporter distributed in almost all tissues. Several 
recent studies regarding GLUT1, especially its prospects as a new drug target for cancer, will 
be explicitly discussed at the end of this review. 
 
Na+-independent glucose transporter (GLUT)  
Na+-independent glucose transporter (GLUT) or facilitative glucose transporter 
transports glucose across cell membranes, which is hydrophobic, in a diffusion-facilitated 
manner without requiring energy but down the concentration gradient between glucose outside 
and inside the cell or vice versa. To date, fourteen members of the GLUT transporter have been 
identified based on the similarity in structure and sequence of amino acids in their constituents. 
The fourteen transporters are then grouped into three main classes based on the similarity of 
amino acid sequences, namely classes I, II, and III. Class I consists of four well-characterized 
transporter members, GLUT1, GLUT4, and GLUT14. Class II has a specific feature that is able 
to facilitate fructose consisting of GLUT5, GLUT7, GLUT9, and GLUT11, also known as the 
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"odd GLUT" group. Class III is the "even GLUT" group consisting of GLUT6, GLUT8, 
GLUT10, GLUT12, and HMIT. This last group has a similar feature in that they have an 
internalization signal that maintains these transporters at the intracellular location under a 
steady state.3,4,6 
Based on the amino acid sequence of GLUT, a protein model was created to estimate the 
orientation of this transporter on the cell membrane. GLUT is estimated to have twelve 
hydrophobic helical domains. This arrangement shows that the amino acid GLUT sequence 
forms twelve loops across the plasma membrane with the amino (NH2-) and carboxyl (COOH-
) ends located on the cytoplasmic side and a large intracellular loop between the 6 and 7 
transmembrane domains. The transmembrane has a high homology between one GLUT and 
another, while the amino acid sequence of the amino ends, carboxyl ends, and loops vary. The 
most obvious structural difference between GLUT Class I, II, and III is the long extracellular 
loop position. The long extracellular loop of class I and II members is between transmembrane 
domains 1 and 2 and have glycosylation sites that increase the efficiency of transport of these 
proteins. Whereas class III members do not have a long extracellular loop between 
transmembrane domains 1 and 2 with potential glycosylated sites between transmembrane 
domains 9 and 10.3,4,6 
The GLUT protein model described above explains that the transfer of glucose by GLUT 
is based on two conformational alternatives. In the first conformation GLUT displays the 
glucose binding site on the extracellular side of the plasma membrane and in the second 
conformation GLUT displays this binding site on the intracellular side. The binding of glucose 
(or other suitable monosaccharide) at one of these sites triggers a conformational change of 
GLUT. In this process monosaccharides can move across the plasma membrane in two 
directions (leaving or entering the cell). Despite their similar structure, GLUTs differ in their 
ability to transport monosaccharides, regulation, and distribution across tissues. 
 
Molecular characteristics of GLUT1 
GLUT 1 is a class I glucose transporter isoform firstly isolated from the HepG2 cell line 
and then successfully cloned and characterized by Mueckler et al. in 1985. The GLUT1 coding 
gene is a solute carrier family 2 member 1 (SLC2A1). SLC2A1 is an official symbol created 
by the HUGO Gene Nomenclature Committee (HGNC). HGNC itself is a committee of the 
Human Genome Organization (HUGO) responsible for approving/assigning unique symbols 
and names for protein-coding genes, ncRNA genes, and pseudogenes to enable clear scientific 
communication. SLC2A1 is located on the short arm of chromosome 1 (1p34.2), consisting of 
10 exons with the complete reference sequence code in the NCBI gene bank is NC_000001.11 
and the reference sequence codes for mRNA and protein are NM_006516.2 (3687 bp) and 
NP_006507.2. respectively.7,8 
GLUT1 is an integral membrane protein that plays a role in the glycolysis pathway as a 
uniporter for glucose with several alternative names: DYT17, DYT18, GTR1, HepG2 glucose 
transporter, MGC141895, MGC141896, PED, SLC2A1, and solute carrier family 2 (facilitated 
glucose transporter), member 1.9, 10 This protein has a reference sequence code from the NCBI 
gene bank, namely NP_006507.2 and the UniProt reference code is P11166. Table 1 shows the 
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Table 1. The results of the chemical parameter analysis of GLUT1 using ProtParam Expasy 
 
Parameter Analysis results 
Molecular weight 54083.78 
Formula C2503H3916N622O664S23 
Atomic composition 
Carbon (C) 2503 
Hydrogen (H) 3916 
Nitrogen (N) 622 
Oxygen (O) 664 
Sulfur (S) 23 
Total number of atoms 7728 
Theoretical pI 8.93 
Number of amino acids 492 
Amino acid composition 
Ala (A) 34 [6.9%] 
Arg (R) 21 [4.3%] 
Asn (N) 14 [2.8%] 
Asp (D) 7 [1.4%] 
Cys (C) 6 [1.2%] 
Gln (Q) 21 [4.3%] 
Glu (E) 24 [4.9%] 
Gly (G) 46 [9.3%] 
His (H) 5 [1.0%] 
Ile (I) 37 [7.5%] 
Leu (L) 59 [12.0%] 
Lys (K) 16 [3.3%} 
Met (M) 17 [3.5%] 
Phe (F) 38 [7.7%] 
Pro (P) 23 [4.7%] 
Ser (S) 35 [7.1%] 
Thr (T) 26 [5.3%] 
Trp (W) 6 [1.2%] 
Tyr (Y) 13 [2.6%] 
Val (V) 44 [8.9%] 
The estimated half-life 
30 hours (mammalian reticulocytes, in vitro) >20 
hours (yeast, in vivo) 
>10 hours (Escherichia coli, in vivo) 
 
GLUT1 is a strong hydrophobic protein consisting of 492 amino acids. Like the class 1 
GLUT structure discussed earlier, GLUT1 has a long NH2 end and COOH end facing the cell's 
cytoplasmic site, a cytoplasmic loop connecting transmembrane domains 6 and 7, and 
glycosylated extracellular loop between transmembrane domains 1 and 2 10. The GLUT1 
activity transport studied in the oocyte of Xenopus laevis frogs showed that GLUT1 transports 
glucose with Km ~3 mM. Under equilibrium exchange conditions, GLUT1 has Km 20 - 21 
mM for 3-O-methylglucose and 5 mM for 2-deoxyglucose. Other monosaccharides that can be 
transported by GLUT1 are galactose, mannose, and glucosamine.2,11,12 GLUT1 also transports 
dehydroascorbic acid, the oxidized form of vitamin C, into the brain.11 This transporter is a 
highly conserved isoform with approximately 74 - 98% identical amino acid sequences 
between species (humans, cattle, rats, mice, chicken, and fish). The glycosylated part of 
GLUT1 is the most often part of differences in amino acid sequences between species.2,11,12 
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GLUT1 is expressed in the highest levels in cells actively proliferating, such as in 
developing embryos, cells forming the blood tissue barrier, erythrocytes, astrocytes, and heart 
muscle.9,10 Erythrocytes and brain cells selectively express GLUT1, so it is known as 
erythrocyte and brain glucose transporter. This protein makes up 3-5% of the erythrocyte 
membrane protein. However, further research has proven that GLUT1 is the glucose transporter 
most widely expressed by tissues in the body such as the eyes, peripheral nerves, placenta, and 
mammary glands. This protein expression is also high in cell lines that are routinely used in 
the laboratory but not by hepatocytes.2,10,13,14 
GLUT1 has two forms based on its molecular weight, namely the 45 kDa and 55 kDa 
forms. These two forms are distinguished only by the length of the glycosylation chain. The 45 
kDa form is found in most cells, including astrocytes, and is thought to be responsible for 
glucose uptake by cells. The 55 kDa form is mainly found in the endothelial cells of the brain 
micro blood vessels and erythrocytes as the main glucose transporter. If there is a GLUT1 
deficiency, the amount of glucose from the blood that enters the brain will decrease. This, in 
turn, can lead to central nervous system dysfunction.2,10,13,14 
 
Biomedical Significances of GLUT1 
The biomedical importance of GLUT1 is mainly genetic, caused by mutations of its 
encoding gene, SCL2A1. The manifestation of this mutation is mainly a deficiency in GLUT1's 
function as the brain's primary glucose transporter. Some of the syndromes associated with 
GLUT1 deficiency are GLUT1 deficiency type 1 syndrome (Glut-1 DS1, OMIM 606777), 
GLUT1 type 2 deficiency syndrome (Glut-1 DS2, OMIM 612126), dystonia, and idiopathic 
epilepsy. Research data on animals and humans show that the safe limit value for glucose 
transport across the blood-brain barrier to meet the needs of brain metabolism and cerebral 
function is very narrow. In the mildest clinical phenotype with intermittent symptoms of 
epilepsy, dyskinesia, and ataxia, it is predicted that there will be a 25-35% decrease in GLUT1 
transporter function, while in the more severe phenotypes, it is estimated that there will be 40-
75% decrease in function. Most SCL2A1 mutations are de novo in nature, whereas this 
mutation is inherited as an autosomal dominant trait in familial cases. A case of autosomal 
recessive transmission has also been reported. All mutations detected were heterozygous, while 
homozygous mutations from GLUT1 were thought to be lethal, causing death in utero.14,15 
Genetic abnormalities in GLUT1 deficiency syndrome or known as De Vivo syndrome, 
have various clinical manifestations. Patients with the missense mutation generally show mild 
to moderate symptoms without a clear boundary of phenotype-genotype correlation. The 
results of other studies showed that mild mental retardation and movement disorders were more 
common in patients with a missense (type A) mutation than those with a translational initiation 
mutation (type B) or multiple deletions in exon (type C). It suggests additional mechanisms at 
work, such as modifying proteins and genes that then influence the phenotype and potentially 
play a role in these complex states' pathophysiology. It is also possible that secondary genes 
and proteins are involved in glucose transport. Patients with identical mutations exhibit 
phenotypic heterogeneity in terms of the range of clinical expression and disease severity.14 
Cases of GLUT1 deficiency syndrome type 1 have been reported in 27 variations of 
protein sequences. One of them was reported by Klepper J et al.16 On the UniProtKB/Swiss-
Prot website, P11166 variant is recorded as p.Arg468Trp variant. The position of variation is 
at position 468 of the wild-type amino acid sequence GLUT1, where the amino acid arginine 
is replaced by tryptophan caused by a missense mutation of the protein-coding gene. This 
variant belongs to the type of "disease" variant, which means that the variant found in patients 
and related diseases has been reported in the literature. Physio-chemically, the amino acid 
changes that occur are large and alkaline amino acids (arginine / R) into large and aromatic 
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amino acids (tryptophan/W). This change has a BLOSUM score of -3, which means that the 
chance of substitution arginine to tryptophan is quite low. The lowest score of BLOSUM was 
-4, with the lowest probability interpretation of amino acid substitutions and the highest 11 
with the highest probability interpretation of substitutions.17 The secondary structure analysis 
of GLUT1 using the Psipred program showed quite clear differences in secondary structure 
between the wild type and the R468W variant even though the amino acid substitution location 
was not in that part but the range of amino acid sequence 380 - 410.17 It shows that substitution 
in one amino acid can causes changes in the secondary structure of GLUT1, which then causes 
malfunctioning. 
GLUT1 expression abnormalities affect a pathway that impacts the pathogenesis of 
diabetic nephropathy. There are indications that variations in SLC2A1 contribute to the 
development of microangiopathy in patients with type 2 diabetes mellitus.18,19 Individuals with 
the Xbal (-) GLUT1 allele are more likely to develop DM that progresses to diabetic 
nephropathy.18 Other studies have shown that GLUT1 regulates cytokines and growth factors 
that act as pro-sclerotic mediators that induce diabetic glomerulosclerosis.20 Furthermore, 
GLUT1 inhibition becomes a further therapeutic approach in diabetes mellitus to prevent 
serious complications. Studies show GLUT1 is a promising therapeutic target for preventing 
diabetic retinopathy. Knockdown of GLUT1 by intraocular injection of siRNA directed at 
SLC2A1 significantly reduced mean retinal glucose levels in diabetic mice. Systemic treatment 
of diabetic mice with forskolin or genistein, which binds to GLUT1 and inhibits glucose 
transport, significantly reduced retinal glucose to the same level seen in non-diabetics.21 
Another similar study by Zhi-Peng You et al. (2017) showed similar results.22 
Research by Yabo Hu et al. demonstrated that 4 mM aspirin administration could inhibit 
glucose uptake and metabolism in vascular endothelial cells by downregulating GLUT1 
expression and suggested that vascular endothelial cell GLUT1 is a potential target for aspirin. 
This research certainly requires further investigation to be applicable to various new disease 
treatment strategies through the GLUT1 inhibition approach.23 
 
GLUT1 and cancer 
Another significance of GLUT1 is its overexpression in cases of malignancy. Cells that 
undergo malignant transformation experience accelerated metabolism and an increase in 
glucose demand. In mammalian cells, glucose transport across the plasma membrane is the first 
step that limits GLUT-mediated glucose metabolism. Increased glucose transport in cancer 
cells is associated with increased and deregulated expression of glucose transporter proteins, 
especially in the overexpression of GLUT1 and GLUT3. Oncogenic transformations in 
mammalian cell cultures lead to increased glucose transport and overexpression of GLUT1 
through interactions with the GLUT1 promoter-enhancing elements. Studies in humans have 
shown that increased expression of GLUT1 in tumors is associated with lower survival. The 
main regulator of GLUT1, especially HIF, also has increased expression in cancer associated 
with the extracellular environment of cancer, which tends to be hypoxic.24,25 
Several studies have shown a relationship between GLUT1 expression and cancer. Among 
them, Kang SS et al. showed that GLUT1 expression was related to the invasion ability of 
breast cancer cell lines where cell lines with high GLUT1 expression had a tendency to be more 
aggressive and potentially malignant than those that did not. Krzeslak et al. reported that 
GLUT1 and GLUT3 expression was significantly increased in poorly differentiated breast and 
endometrial tumors compared with well-differentiated ones. Increased mRNA and GLUT1 
protein levels have also been reported in colorectal, thyroid, lung, stomach, head and neck, 
bladder, kidney, and endometrial carcinomas. Carvalho KC et al. demonstrated that GLUT1 
was expressed in varying degrees by tumor type. Sarcomas, melanomas, hepatoblastomas, and 
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lymphomas do not express GLUT1, which means that there are other glucose transport 
mechanisms that play a role in these tumor types.26,27,28 
GLUT1 also has biomedical significance in cancer stem cells. Research by Wanandi et al. 
showed an increase in the expression of the breast CSC GLUT1 gene CD24- / CD44 + in 
hypoxic conditions, which correlated with the increased expression of HIF1α. This increase in 
GLUT1 expression was followed by an increase in glucose consumption. Although this study 
did not measure the activity of the four key enzymes that regulate glycolysis (hexokinase, 
glucokinase, phosphofructokinase, and pyruvate kinase), it seems that most of the pyruvate 
formed is converted to lactate as indicated by increased LDH activity accompanied by 
increased production of lactate by the cells. These results show that under hypoxic conditions, 
HIF1α regulates the glucose metabolic state of CD24- / CD44 + breast CSCs in the form of 
increased anaerobic glycolytic activity.29  
 
GLUT1 inhibition as a novel cancer therapeutic strategy 
Evidence showing increased glucose consumption in cancer cells versus healthy cells 
implicates the role of GLUT1 and other roles of this protein in oncogenesis, paving the way 
for new strategies in cancer therapy. Biomedical studies on GLUT1 inhibition in various types 
of cancer using natural and synthetic compounds have been carried out in the last decade with 
promising results. Some examples of GLUT1 inhibitor compounds that have been studied on 
various types of cancer cells and animal models are shown in Table 2. 
 
Tabel 2. Studies of GLUT1 inhibition by synthetic and natural compounds  
in various types of cancer 











the growth of a 

















cell growth in 
cancer cell lines 
and cancer growth 
in a nude mouse 
model. 
31 





induced cell cycle 
32 
38 Indonesian Archives of Biomedical Research 
Volume 1 Issue 1, January-June 2021 
 
 
©Copyright by © Copyright by Konsorsium Ilmu Biomedik Indonesia (KIBI) 
 
















in ovarian cancer 













leading to reduced 
influx of glucose 






34 Cervical cancer HeLa 
Breast cancer MCF-7 
Ovarian cancer 
































Neuroblastoma  SH-SY5Y 





the expression of 
hypoxia-inducible 









39 Indonesian Archives of Biomedical Research 
Volume 1 Issue 1, January-June 2021 
 
 
©Copyright by © Copyright by Konsorsium Ilmu Biomedik Indonesia (KIBI) 
 















Apart from the direct effect that causes a decrease in GLUT1 expression and a decrease 
in glucose uptake, which then results in the suppression of tumor growth, inhibition of GLUT1 
has also been shown to increase cancer cells' sensitivity to chemotherapy agents such as 
cisplatin and adriamycin.39,40,41 GLUT1 inhibition also increases the sensitivity of cancer cells 
to radiotherapy.42 
Inhibition of GLUT1 appears to provide new hope for cancer treatment strategies. 
Various compounds have been shown to be able to inhibit the expression of GLUT1, which 
then suppress tumor growth both in vitro and in vivo. A more detailed understanding of these 
compounds' specific inhibitory mechanisms against cancer cells and their delivery mechanisms 
is needed. Thus, the inhibitory effect does not affect healthy cells because, as stated in the 
beginning, GLUT1 is the most widely expressed glucose transporter in the body tissues and 
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ABSTRACT 
Because of its virulence and ability to survive, the incidence of infection caused by Streptococcus suis (S. suis), 
an emerging zoonotic pathogen, is expected to increase significantly. A biofilm-forming process, which is a 
cornerstone of chronic infection, influences the survival rate of S. suis. The mechanism helps bacteria to live 
longer in host tissues, form colonies, escape immune clearance, and share genetic information. At this moment, 
the most studied regulatory mechanism of S. suis biofilm formation is Quorum Sensing (QS), mainly on LuxS/AI-
2-mediated QS system, in which AI-2 is the most closely related molecule to biofilm formation. In this system, 
LuxS acts as the key player in the process. The understanding of biofilm formation in S. suis, especially the 
LuxS/AI-2-mediated QS system, is a valuable contribution to future therapeutic research frameworks. 
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Streptococcus suis (S. suis) is a gram-positive facultative anaerobic bacteria which is 
well-known as a commensal microorganism at the respiratory system of the swine. On the other 
hand, in human, this bacteria is a potentially serious threat to induce fatal complications such 
as meningitis, septic shock, endocarditis, and peritonitis after the onset of infection (1, 2). The 
majority of S. suis infection was found in areas with pig-farming and pork industries. From 
2002 until 2013, nearly more than 1.500 cases of S. suis infections was reported globally, most 
of them came from Asian countries (3). South East Asia was considered to be a potentially 
threatened area with its high amount of pork consumption and swine-related industries. A 
research conducted in Sanglah Hospital, Bali, from 2014 until 2017 has shown that there were 
44 cases of S. suis meningitis confirmed by Polymerase Chain Reaction (PCR) of the patients’ 
cerebrospinal fluid sample (4). The incidence of S. suis infections in human is predicted to 
elevate significantly due to unavailability of vaccines as the specific protection and the ability 
of its virulence factors to induce catastrophic pathological mechanisms (5).  
The most prevalent strain of S. suis which has isolated in human is serotype 2 (86,5%), 
followed by serotype 14 (2,3%), and 1 (0,6%). Streptococcus suis serotype 2 (SS2) has 
considered to be the most aggressive subtype among all serotypes (6). The exacerbation of 
inflammatory pathway is a hallmark of SS2 infection in both human and swine. Biofilm 
formation by S. suis can cause a chronic infection that is especially difficult to treat when the 
pigs' immunity decreases (7). Biofilm forming ability has known to be a foundation of chronic 
infection (8) and the most effective mechanism to hinder from host’s immunity. By aggregating 
into a biofilm, microorganisms may escape the dangerous host environment. The activity 
makes it possible for bacteria to live longer and form colonies in host tissues, as well as prevent 
immune clearance and share genetic information (9). To date, studies related with the 
42 Indonesian Archives of Biomedical Research 
Volume 1 Issue 1, January-June 2021 
 
 
©Copyright by © Copyright by Konsorsium Ilmu Biomedik Indonesia (KIBI) 
 
mechanism of S. suis biofilm formation are mainly focused Quorum Sensing (QS), mainly on 
LuxS/AI-2-mediated QS system. The knowledge about biofilm formation in S. suis, 
particularly on LuxS/AI-2-mediated QS system, is a worthwhile contribution in constructing 
research frameworks in future therapeutic strategies (8). 
 
The General Concepts of Bacterial Biofilm and its Formation  
Biofilm is an architecturally complex communities in which microorganisms are bound 
to a substratum and trapped in a matrix of polymetric substances that provide them with a high 
degree of tolerance and resistance (10). Biofilms have a number of effects on humans, the 
majority of which are harmful (11). In general, all biofilms contain an extracellular matrix that 
holds cells in a pack. This matrix is frequently made up of a polysaccharide biopolymer as well 
as proteins and Deoxyribonucleic Acid (DNA) (12). Matrix exopolysaccharide has a wide 
variety of properties depending on growth conditions, medium, and substrates. Biofilms have 
adhesive proteins in their extracellular matrix. For example, Biofilm-associated proteins (Bap) 
are present in the matrix of Streptococcus aureus (13). Extracellular DNA, in addition to 
exopolysaccharides and proteins, provides structural integrity to the biofilm, which was 
previously believed to be the product of cell lysis and subsequent genomic DNA release. The 
biofilms are stabilized by the eDNA (14).  
There are five stages of bacterial biofilm formation in general: initial/reversible 
attachment, irreversible attachment, formation of micro-colonies, maturation, and cellular 
detachment or dispersion. The bacteria make contact with the surface through the cell pole and 
are transiently bound to the substratum during the reversible attachment stage. There was a 
reorientation to the longitudinal cell axis, cell cluster growth, nonmotile, and activation during 
irreversible attachment. During maturation, layered cells form clusters, and at the end of the 
process, the maximum cell cluster formation was observed, reaching a thickness of 100 m. The 
majority of cells were also displaced from the substratum at this point. Dispersion, the final 
stage of biofilm formation, revealed changes in cell cluster composition, the formation of pores 
and channels, and dispersion (15). Depending on environmental conditions and unique strain 
characteristics, different bacteria use different mechanisms to form biofilms (16).  
Several studies have shown that S. suis can form biofilm in vitro using various biological 
models. A number of factors influence the formation of biofilm in S. suis, including the OCT 
protein, the signaling molecule autoinducer-2 (AI-2), and the collagen-binding 40 (cbp40) (8). 
There are four categories of bacterial biofilm’s regulatory mechanism called Extracytoplasmic 
Function (ECF) signaling pathway, Two-Component System (TCS), intracellular second 
messenger cyclic diguanylate (c-di-GMP), and bacterial Quorum Sensing (QS) system (17-20). 
The most studied regulatory mechanism of S. suis biofilm formation at the moment is QS, 
which is primarily based on the LuxS/AI-2-mediated QS framework, with AI-2 being the most 
closely related molecule to biofilm formation. In S. suis, the luxS gene controls biofilm 
formation (10). According to one study, inhibiting the expression of luxS in Riemerella 
anatipestifer can reduce AI-2 production, which has a direct impact on biofilm formation (21).  
 
The LuxS/AI-2-mediated Quorum Sensing System  
In S. suis, biofilm formation is largely influenced by bacterial intercellular 
communication through QS, which is involved in a number of physiological processes 
including extracellular protein synthesis, biofilm maturation, and virulent factor gene 
expression. QS is a cell-to-cell communication system that controls the expression of genes in 
bacteria to promote organized adaptation of various genes (22).  When bacteria are faced with 
a difficult situation or climate, the QS system sends information signals between cells to 
increase the number of bacteria, biofilm formation, and EPS production, allowing bacteria to 
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better adapt to their surroundings (8). QS systems can be divided into some classes. They are 
LuxR-LuxI systems of Gram-negative bacteria, the auto-inducing peptide of Gram-positive 
bacteria, and the LuxS/AI-2 system found in both Gram-positive and Gram-negative bacteria 
(10). 
The general mechanism of QS is to ensure that a bacteria's capacity to generate and 
release signaling molecules known as autoinducers (AIs) is not impaired (23, 24). The QS-
controlled mechanism, which is a molecular signal network regulated by the luxS gene 
encoding the S-ribosylhomocysteinase (LuxS) enzyme found in virulent SS2, allows 
Streptococcus suis to form biofilms. LuxS has been implicated in enhancing Auto Inducer-2 
(AI-2) biosynthesis, adhesions, biofilm formation, cell metabolism, and resistance to host 
immune responses and antimicrobial therapy in a number of studies (22, 25, 26).  
The gene that encodes LuxS; the luxS gene, is highly conserved in bacteria. High identity 
and similarity of luxS genes were found in Streptococcus mutans, Streptococcus pyogenes, 
Streptococcus pneumoniae, Lactococcus lactis, Clostridium perfringens, Neisseria 
meningitidis, Escherichia coli, and Haemophilus influenza (27). LuxS is involved not only in 
the development of the AI-2 signaling molecule, but also in central bacterial metabolism and 
is a component of the activated methyl cycle (28). LuxS is specifically involved in the 
conversion of S-adenosine homocysteine to S-adenosylmethionine (SAMe). 
SAMe is a typical biomolecule that primarily functions as a methyl donor. The loss of 
SAMe feature and inhibition of AI-2 synthesis occurs when luxS is mutated or deleted. LuxS 
is a critical component of the LuxS/AI-2-mediated QS system. AI-2 is a byproduct of bacterial 
methyl metabolism that helps activated methyl cycles regulate their metabolism (29). The 
methyl group is extracted from SAMe and then converted into S-Adenocylhomocysteine 
(SAH), which is a toxic metabolite, in the LuxS/AI-2 system. SAH is then converted to adenine 
and S-Ribose Homocysteine (SRH) by a 5'-methylthioadenosine/S-adenosyl homocysteine 
nucleosidase (Pfs). Following that, SRH is converted to 4,5-dihydroxy-2,3-pentanedione 
(DPD) and homocysteine acid (HCY) by LuxS (30). LuxS then catalyzes the cleavage of SRH's 
thioether linkage, resulting in HCY and DPD. Self-cyclization creates DPD, which is then 
transformed to AI-2 (Figure 1). As bacterial density grows, AI-2-mediated QS is activated (31).  
When a small amount of AI-2 was applied to the growth medium, the ability of S. suis to 
form biofilm was greatly increased, while high concentrations of AI-2 inhibited the ability to 
form biofilm. At 24 hours, adding 2 µM AI-2 to the mix significantly improved biofilm 
formation, but had no effect at 48 hours (32). The capacity of S. suis to form biofilm is 
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Figure 1. AI-2 Synthesis Pathway in S. suis. SAMe, S-adenosylmethionine; SAH,   
thioglucoside homocysteine; SRH, thioglycoside-type homocysteine; DPD, 




The rising number of S. suis infections, coupled with the newly discovered importance of 
the LuxS/AI-2 system in S. suis cell-to-cell contact and virulence, necessitates the production 
of antibacterial strategies that target the LuxS/AI-2-mediated QS system. In order to regulate 
bacteria by inhibiting pathogen signaling, a better understanding of bacterial regulation and AI-
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ABSTRACT 
Because of its virulence and ability to survive, the incidence of infection caused by Streptococcus suis (S. suis), 
an emerging zoonotic pathogen, is expected to increase significantly. A biofilm-forming process, which is a 
cornerstone of chronic infection, influences the survival rate of S. suis. The mechanism helps bacteria to live 
longer in host tissues, form colonies, escape immune clearance, and share genetic information. At this moment, 
the most studied regulatory mechanism of S. suis biofilm formation is Quorum Sensing (QS), mainly on LuxS/AI-
2-mediated QS system, in which AI-2 is the most closely related molecule to biofilm formation. In this system, 
LuxS acts as the key player in the process. The understanding of biofilm formation in S. suis, especially the 
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Indonesia is an archipelago country and have more biodiversity, including the seahorse. 
The marine aquaculture centers have an cultivated this animal, because they have high 
economic value which is made Indonesia as one of the largest exporting countries in Asia 
(Nasution et.al, 2019; Wang et.al, 2020). 
Seahorses used in traditional medicine which is have an several effects, such as increasing 
stamina and hematopoesis, anti-fatigue, anti-oxidant, anti-tumor, anti-inflammatory, anti-
aging, and important for fertility because have an aphrodisiac effects (Adam et.al, 2014; Kim 
et.al, 2016; Nasution et.al, 2019;  Safryna, 2020; Sanaye et.al, 2014;  Wang et.al, 2020; Zhang 
et.al, 2017).   
The function in fertility, it is suggested that bioactive compounds is steroid testosterone, 
which in animal tissue it is usually used in aphrodisiacs for male. The function of this hormone 
is to stimulate the spermatogenesis, increasing the development and activity from genital organ 
(Safryna et.al, 2020). In addition, for pharmacology this hormone can be effect hypothalamus 
to release Gonadotropin Releasing Hormone (GnRH) in reproductive system (Zitzmann et.al, 
2013). 
Nowadays, one of the health problems in Indonesia is infertility, which is one of the 
factors from the male. Male infertility influences from many factors, including from 
spermatogenesis and testis disorder (Li et.al, 2020; Zitzmann et.al, 2013).  Nowadays, the 
treatment for infertility used GnRH therapy, which is used to influences the maturation of cells, 
and increasing testosterone levels, and increasing the germ cells (Biers, 2010; Li et.al, 2020). 
GnRH therapy can use a analogues GnRH (GnRHa) which is reported that 3100 patients 
through 50 publications given the GnRHa. It is still controversy between the impact in 
reproductive system and needed the study (Li et.al, 2020; Schwentnr et.al, 2005). It is caused 
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by several things, such as a large doses and long periods, and it can make a mutation in gene 
receptor GnRH when the therapy is failure (Zitzmann et.al. 2013). 
Seahorse have an active hormone steroid testosterone from natural product which is 
suggested an alternative therapy for GnRH.  Furthermore, the bioactive compound steroid in 
seahorse can be optimally to target organs, which is the reproductive system.  To evaluate the 
function of bioactive compound, in this decade it can be using modern science and technology. 
It can be done through drug delivery systems with several carrier systems, such as a 
nanoparticle (Schwentner et.al, 2005). The target organ achievements by delivery through 
nanoparticles are evaluated using transmission electron microscopy (TEM). 
 
Seahorses (Hippocampus sp) 
Seahorse is one of the unique fish, because not only about the body's morphology, it is 
also the male is pregnancy (Blumenfeld, 2019). The female will give the eggs to male individu 
and spermatids will be included in the pore that fertilization occurs (Zhang et.al, 2017). The 
Male will incubate the eggs in the anteriomesial /central pore near the abdomen (Koldewey, 
2010). 
The species of seahorses in Indonesia are Hippocampus barbouri, H. comes, H. histrix, 
H.  kelloggi, H. bargibanti, H. spinosissimus, H. trimaculatus and H. kuda (Meikasari et.al, 
2020). Seahorse is a natural product and promising used to be the potential drug for medical 
use (table 1) (Chen et.al, 2014; Kumaravel et.al, 2012; Meikasari et.al, 2020). 
 




Medical Used Ref 
1 Amino acids  Anti-inflammatory, inluence 
the histology vesicular seminalis 
1, 9 
2 Protein  Increasing Hb 3 
3 Alkalase and 
pepsin 
Increasing testosterone and 
weight testis 
6 
4 Steroid, taurine Aphrodisiac  7 
5 Amino acid, 
steroid, fatty acid, 
microelement 




7 Steroid and fatty 
acid 
Treatment BPH 20 
8 Steroid and 
saponin 
Vitality and immune respone  21 
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Gonadotropin Releasing Hormone (GnRH) 
GnRH is decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) produced 
from hypothalamus as the main hormone reproductive in Hypothalamus-Pitutary Gonad axis 
(HPG Axis) in vertebrate (Gopurappilly et.al, 2013; Jin, 2014; Sakhteman et.al, 2016). GnRH 
hormones has 30 isoforms, 15 in vertebrates and 15 invertebrates (NCBI, 2020). GnRH 
influences the spermatogenesis, steroidogenesis, and feedback mechanism in gonads. In 
mammals, it still consists GnRH1, GnRH2 and GnRH3, but only the GnRH1 and GnRH2 have 
the same amino acids in vertebrate.  In humans, GnRH have a similar name as protein a 
progonadoliberin. It is located on chromosome 8p.2-p.21 with 276 bp which is translates from 
92 amino acids (Jin, 2014; Sakhteman et.al, 2016). This gene encodes to stimulate the release 
of LH and FSH, and when this gene has a mutation it can be caused a hypogonadotropic 
hypogonadism in human (Uniport, 2020). GnRH in seahorse has a similar name protein as a 
gonadoliberin (NCBI, 2020).  
GnRH has a G protein receptor which is transmembrane proteins to regulating fertility 
(Jin, 2014; Sakhteman et.al, 2016). GnRH receptors can be found in humans and the teleost 
such as seahorse. In vertebrate, HPG Axis will be expressing a various GnRH. In mammals it 
carried out by GnRH in hypothalamus which binds the G receptors stimulate to release a 
gonadotropin, FSH and LH in gonad (Zhang et.al, 2018). Nowadays, there is an G receptor 
from kisspeptin gene as a transcription promote of the GnRH (Jin, 2014; Sakhteman et.al, 
2016).   
Structure of GnRH in human and seahorse have a different structure from 
swissmodel.expasy tools (fig.1), but they have the same kisspeptin gene which is regulate the 
hypothalamus in vertebrate (Zhang et.al, 2018).  
The kisspeptin gene is also found in the teleost group of fish, such a seahorse which is a 
key regulator of reproduction and sensitive with steroid (Gopurappily et.al, 2013; Zhang et.al, 
2018) Most teleost fishes have kiss 1 and kiss 2, furthermore in mammals there is only one 
kisspeptin gene (kiss 1). Kisspeptin gene in seahorse directly regulates GnRH, although it is 
needed the study. However, the previous study reported the function is the same with mammals 
as an activator the reproductive axis through the stimulation of GnRH secretion (Zhang et.al, 
2018).  
The treatment for male with infertility is being developed, for example with testosterone 
therapy. One of them is with GnRH therapy. But now, several studies were reported have an 
several problems. There are about the uncomfortable in patients, cost therapy is too high, long 
period, and influenced from antibody from each individual (Zitzmann et.al, 2013).  
 Zhang et.al, (2018) reported that in teleost, there is still widely underexplored, because 
the kisspeptin is still debate, but the previous study suggests that fish kisspeptin have a similar 
with mammalian kisspeptin, which is the key to activator the reproductive axis. It can be 
investigated to be an alternative as a substitute therapy for infertility in male. But, the gene 
kisspeptin between in humans and seahorse have a different structure from pymol tools (fig.2). 
In this condition, it is needed the study to answer the question is there a seahorse extract as a 
natural product can be a medical use for male infertility to replace a GnRH therapy, and it can 
be a novel therapeutic targets and interventions. 
The previous study has reported by Zhang et.al (2018) that kisspeptin gene suggest 
involved the regulation in reproductive function of pubertal onset and gonadal development, 
and also in seahorse male pregnancy there is regulating testosterone synthesis. In assisted 
reproduction, study used next generation sequencing was found the Kisspeptin (kiss 1) suggest 
as a gene which is modulate hormone levels and reproductive outcome and can be a novel 
50 Indonesian Archives of Biomedical Research 
Volume 1 Issue 1, January-June 2021 
 
 
©Copyright by © Copyright by Konsorsium Ilmu Biomedik Indonesia (KIBI) 
 
therapeutics targets (Blasco et.al, 2020; Patel, 2020; Trevisan et.al, 2020). Another study by 
Hestiantoro et.al (2019) reported that kisspeptin concentration was associated with 
postmenopausal because the serum concentration was lower. In the other study was reported, 
kisspeptin was reported as a potential biomarker in across pregnancy and can be a future study 
in reproductive system such as for Polycystic ovarian syndrome (Hu et.al, 2019; Rodrigues 
et.al, 2019; Talbi, 2019). Khamis et.al (2019) also reported that undergoing kisspeptin 
treatment as in vitro fertilization and approaches to increasing the reproductive role. Kisspeptin 
also reported by Oride et.al, (2020) that promising to increasing overcoming diabetic testicular 
dysfunctions which is enhancing spermatogenesis, as well as reducing the testicular 
inflammation and apoptosis.  The fertility drugs may act on kiss 1 expressing neurons because 
it was modulating the HPG axis (Chenthamara et.al, 2019). 
In this decade, the technology in science have been develop. There is a drug delivery 
system which is combine between a medicine and high technologies. When we want to know 
about the bioactive compound in seahorse can be use in medicine as a male infertility, one of 
them technology we can used the nanotechnology. 
 
Nanotechnology in Reproductive System 
Nanotechnology is the design, characterization, production and application of structures, 
devices and compilation systems between sciences and engineering with a nanometer scale (1-
100nm) or one millionth of a meter (Albanese et.al, 2012; Brohi et.al, 2017). 
Study about nanotechnology is conducted to determine the interaction of nanoparticles 
with biological systems is a nano-bio interaction. Nanoparticles (NP) interact with cell surface 
membranes. Once bound to the receptor, nanoparticles in the cell through endocytes mediated 
by the receptor (Falchia et.al, 2018).  
Nanoparticles is synthesized from various organic or inorganic materials such as lipids, 
polysaccharides, metals, proteins, and synthetic or natural polymers. Formulation of the drug 
with nanoparticles are currently developing to increasing efficiency, prolongation of drug in 
circulation, targeting specific tissues, therapeutic reactions, and side effects or toxicity 
(Albanese et.al, 2012; Falchi et.al, 2018). 
 The effects of nanoparticles in cellular and tissue level are not clearly. They are some 
effect, that used in male and female reproductive systems at the clinical, cellular and molecular 
levels. In the male reproductive system, it is can be influences fertility with increasing the 
quality of sperms from in vivo or in vitro (Falchia et.al, 2018; Falchi et.al, 2018). 
The previous studies by Safaa et.al, (2016) reported that function of nanoparticle in 
reproductive system, study about efficiency of NP cerium oxide (CeO2) can protect viability 
and increasing the motility of sperm. In the other study, they reported with addition of 5 μg/mL 
of vitamin E combined with 1% Nano-Se can be improve semen quality in chickens (Rezvanfar 
et.al, 2013). Study about supplementation from SeNPs can protect the quality of spermatozoa 
(motility, DNA integrity) and spermatogenesis from oxidative damage caused by anticancer 
agents in the male reproductive system (Saraf, 2010). 
Nanoparticles is one of the technologies which is increasing the bioavailability of active 
substances in seahorses. It can be influences about the smaller size can increasing the delivery 
of active substances with low solubility because they contain lipids and cholesterol. 
Nanoparticles will be transferred into cells through endocytosis transitions. Nanonization of 
natural products provides benefits by increasing active substances, small therapeutic doses, and 
increasing absorption and bioavailability in the body (Kumar et.al, 2019). 
To evaluating the mechanism from nanoparticle in human body, we can use a gold standar 
for this with a transmission electron microscopy.  
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Evaluation of Nanoparticles in Reproductive System 
Transmission electron microscopy (TEM) is the most technique used to characterize 
nanoparticles, and to assess the safety and toxicological potential of a nanoparticle. TEM is a 
gold standard for  nanoparticle because such as a reason, there are about the resolution in 
nanometer sizes in the range 1-100 nm, image display with atomic dimension, it can describe 
the physical properties quantitatively (size, shape, and surface morphology), and  also can 
determine the agglomeration of a material (Lina et.al, 2013; Masta et.al, 2020). 
In addition, TEM also has a limitations, because the analysis process depends on the 
transfer of representative fractions of samples containing sufficiently large amounts of particles 
to the specimen carrier (TEM grid) which is affected by the purification process and the 
concentration of the sample and the specimens must be very thin (Walther, 2017). 
TEM produces an electron beam from transmitted to the specimen. The electron interacts 
with the specimen and transformed into a scattered electron. Electrons will be focused by 
electromagnetic lenses that are projected the screen to produce diffraction, contrast-amplitude 
images, phase-contrast images or various image variations (Hu et.al, 2019). Interpretation data 
from the TEM obtained interactions between electrons and matter, giving rise to a dynamic 





Seahorse (Hippocampus sp) as a natural product with bioactive compound steroid 
testosterone has the oppurtinities to investigate the further study as a substitute for GnRH 
therapy for male infertility, it is because the same structure and receptor protein in human and 
needed the study. The treatment can be evaluation with nanotechnology to know the efficient 
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